Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

uctive quarter," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "We delivered solid financial results, set in place a number of catalysts that will drive near-term growth, and continued to build the company to grow beyond 2011."

Over the next 12 months, Genzyme anticipates six potential approvals for new products or broader indications for existing products. These catalysts will provide significant near term momentum:

-- Genzyme expects FDA approval by the end of this year for alglucosidase alfa (Myozyme(R)) produced at the 2000L bioreactor scale, following the submission of a BLA on May 30. European approval of Myozyme produced at the 4000L scale is expected in the first half of next year.

-- The company anticipates that the labeling for Renvela(R) (sevelamer carbonate) will be expanded by mid-2009 to include the treatment of chronic kidney disease patients with elevated phosphorus levels who are not on dialysis. Genzyme, along with two other companies, submitted a position paper to the FDA in May regarding this expanded use of phosphate binders.

-- Genzyme also expects that the labeling for Clolar(R) (clofarabine) will be expanded by the middle of next year to include its use in treating adult patients with acute myelogenous leukemia. The company plans to file supplemental marketing applications this year to broaden Clolar's indication.

-- Genzyme expects to launch Mozobil(TM) (plerixafor) in the United States and Europe during the first half of next year, following regulatory approval. The company submitted marketing applications for the product last month. Mozobil is intended to enable patients with certain types of cancers to successfully receive a stem-cell transplantation.

-- FDA action on Genzyme's marketing application for Synvisc-ONE(R) (hylan G-F 20) is anticipated this year. The company submitted a response to the agency in June that included additional analysis and data requested in a Nov
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... Same Quarter Last Year - ... - FY08 Revenue Guidance Raised - - Conference ... MINNEAPOLIS, Feb. 11 Uroplasty, Inc. (Amex:,UPI), a medical device company that ... reported record net sales of $3.7 million for the third quarter of,fiscal ...
... Anesiva,Inc. (Nasdaq: ANSV ) announced today the appointment ... Mr. Janney previously served on Anesiva,s,board from November 2000 ... the merger of Anesiva and AlgoRx Pharmaceuticals., "Dan ... directors,and we are very pleased to welcome him back, ...
... INDIANAPOLIS, Feb. 8 Semafore Pharmaceuticals Inc.,today announced ... and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer,will ... programs at,2:45 p.m. EST on Wednesday, Feb. 13, ... New York City., The update will include ...
Cached Biology Technology:Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 2Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 4Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 5Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 6Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 7Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 8Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 9Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 10Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3Semafore to Present at BIO CEO & Investor Conference 2
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... , ,People,s moral responses to similar situations change as ... University of Chicago that combined brain scanning, eye-tracking and ... morally laden scenarios. Both preschool children and adults ... assessing whether a perpetrator had done something wrong. Nonetheless, ...
... expensive sole fillets or cod caught in the North Sea ... examples of types of fraud in the fisheries sector. A ... based on genetics, genomics, chemistry and forensics - can provide ... fish product come from.where was this fish caught.is it wild ...
... infects people with cystic fibrosis could help combat other ... Warwick Universities. Continuous use of existing antibiotics means ... all over the world. New antibiotics are urgently needed ... the MRSA superbug. Now a surprising source ...
Cached Biology News:Changes in brain circuitry play role in moral sensitivity as people grow up 2Changes in brain circuitry play role in moral sensitivity as people grow up 3What fish is on your plate? 2Cystic fibrosis bacteria could help fight back against antibiotic resistance 2
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... can be used for the identification of potential ... renal and other diseases. Due to the fact ... amounts, it provides an attractive alternative to blood ... The ProteoSpin Urine Protein Concentration Micro Kit ...
Biology Products: